SS-31 illustrates why a short peptide can still require a detailed structural specification. The abbreviation does not encode every residue modification or terminal feature. An exact research request should state the modified sequence and ask how the supplier’s offered chemical form and analytical evidence map to that definition.
Retain the modified residue names
An original experimental SS-31 publication defines the peptide as D-Arg–2′,6′-dimethyl-tyrosine–Lys–Phe-NH2. For this identity review, the important features are the D-arginine designation, the modified tyrosine and the terminal amide. Do not simplify this into an ordinary unmodified one-letter sequence. The paper supports the stated research identity, not the composition or performance of a catalog batch.
Expand abbreviations before approving a structure
Dmt is useful shorthand only when its chemical definition is attached. Ask the supplier to expand the abbreviation, identify residue stereochemistry and provide the complete offered structure. Keep the C-terminal amide explicit rather than treating NH2 as optional punctuation. The worksheet deliberately separates covalent features from the salt or counterion statement so a reviewer can see which proposed change affects which part of the specification.
| Field | Identity feature | Order question |
|---|---|---|
| Residue 1 | D-Arg designation | Same stereochemical requirement? |
| Modified residue | 2′,6′-dimethyl-tyrosine | Expanded Dmt definition? |
| C terminus | Phe-NH2 | Amidation explicitly represented? |
| Chemical form | Separate salt / counterion statement | Actual offered preparation? |
| Evidence | Sample-linked structural and purity scope | Which distinctions are addressed? |
Confirm the supplied chemical form separately
A synthesis paper may describe a particular isolated salt, but that does not establish a universal commercial form. A published SS-31 synthesis study illustrates a specifically described preparation. Use such descriptions to formulate questions, not to fill the supplier’s missing field. Ask what form is actually quoted, which additional constituents are declared and how the mg basis is defined for that material.
Ask what the analytical scope can distinguish
An expected mass comparison is one part of an identity review, not a complete answer to every stereochemical and modification question. Request the named sample, method scope and any supporting records the laboratory requires. Keep purity reporting separate from structural evidence and content basis. If the offered documentation does not address a project-critical feature, record the gap and ask about additional characterization instead of interpreting an incomplete summary as confirmation.
Preserve the structural baseline across alternatives
If a supplier proposes a different terminus, modified residue or supplied form, request a marked alternative. Do not hide those changes under the same SS-31 title or merge their reports. A repeat-order record should retain the accepted structure and the document scope, while batch-specific evidence is checked again. This article concerns research-material definition only; it does not transfer experimental results into clinical claims or provide administration advice.
Before closing this review
- D-Arg has not been flattened into ordinary Arg.
- Dmt has an attached definition.
- Amidation is visible in the structure.
- A published preparation is not assumed to be this lot.
Continue with review the relevant catalog record; prepare a precise material inquiry. Save the relevant product or guide link alongside the written response so another reviewer can reconstruct the decision.
Editorial scope: research-material procurement and document review. Not medical guidance, dosing instructions or a claim of suitability for human use. Requirements and availability must be confirmed for the quoted material.
